Expertise in
1
conditions

Dr. Hetal R. Vachhani

Hematology
VCU Health System Stony Point
9000 Stony Point Pkwy, 
Richmond, VA 
Accepting New Patients
Offers Telehealth
Expertise in
1
conditions
VCU Health System Stony Point
9000 Stony Point Pkwy, 
Richmond, VA 

Overview

Hetal Vachhani is a Hematologist practicing medicine in Richmond, Virginia.

Dr. Vachhani is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Adult Immune Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 6 clinical trials. Dr. Vachhani is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MI

Hospital Affiliations

Medical College Of Virginia Hospitals
Vcu Health Tappahannock Hospital

Languages Spoken

English
Hindi

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

VCU Health System Stony Point
9000 Stony Point Pkwy, Richmond, VA 23235
Other Locations
Virginia Commonwealth University Health System Authority
1250 E Marshall St, Richmond, VA 23298

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: May 29, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: April 29, 2026
Intervention Type: Other, Drug
Study Drugs: Palbociclib, Letrozole, Fulvestrant
Study Phase: Phase 2
View 5 Less Clinical Trials

5 Total Publications

Germline BRCA2 Mutation and Lynch Syndrome in a Patient With Multiple Primary Malignancies.
Germline BRCA2 Mutation and Lynch Syndrome in a Patient With Multiple Primary Malignancies.
Journal: Case reports in oncological medicine
Published: February 19, 2025
Similar Doctors
Expertise in
41
conditions
Dr. Andrew Poklepovic
Hematology | Oncology
Expertise in
41
conditions
Dr. Andrew Poklepovic
Hematology | Oncology
Referral may be required

Vcu Health Massey Cancer Center Oncology Clinic

1001 E Leigh St, Fl 4, 
Richmond, VA 
 (5.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Poklepovic is a Hematologist and an Oncologist practicing medicine in Richmond, Virginia. Dr. Poklepovic is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Melanoma, Synovial Sarcoma, Angiosarcoma, Merkel Cell Carcinoma, and Bone Marrow Aspiration. Dr. Poklepovic is currently accepting new patients.

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

UVA Health Emily Couric Clinical Cancer Center

1240 Lee St, 
Charlottesville, VA 
 (60.8 miles away)
434-924-9333
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Craig Portell is a Hematologist practicing medicine in Charlottesville, Virginia. Dr. Portell is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Marginal Zone Lymphoma (MZL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Portell is currently accepting new patients.

Expertise in
30
conditions
Dr. Sosipatros A. Boikos
Hematology | Oncology
Expertise in
30
conditions
Dr. Sosipatros A. Boikos
Hematology | Oncology
Referral may be required

Virginia Commonwealth University Health System Authority

1250 E Marshall St, 
Richmond, VA 
 (7.5 miles away)
804-828-7999
Languages Spoken:
English, Greek
See accepted insurances
Accepting New Patients

Sosipatros Boikos is a Hematologist and an Oncologist practicing medicine in Richmond, Virginia. Dr. Boikos is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Synovial Sarcoma, Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Neuroendocrine Tumor, and Bone Marrow Aspiration. Dr. Boikos is currently accepting new patients.

Frequently Asked Questions about Dr. Hetal R. Vachhani

How do I make an appointment with Dr. Hetal R. Vachhani?

You can book an appointment with Dr. Hetal R. Vachhani by calling their office at 804-327-3055. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Hetal R. Vachhani a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Hetal R. Vachhani is classified as an Advanced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Hetal R. Vachhani specialize in?

While Dr. Hetal R. Vachhani is a Hematology, they have specific expertise in Multiple Myeloma, Smoldering Multiple Myeloma, and Adult Immune Thrombocytopenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Hetal R. Vachhani participate in research or clinical trials?

Yes. Dr. Hetal R. Vachhani has published 5 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Hetal R. Vachhani's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Hetal R. Vachhani accept my insurance?

Dr. Hetal R. Vachhani accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 804-327-3055 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vachhani's expertise for a condition
ConditionClose
      View All 33 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile